The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy and Safety of 6.25 mg t.i.d. Feverfew CO2-Extract (MIG-99) in Migraine Prevention — A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study
Abstract
The efficacy and tolerability of a CO 2-extract of feverfew (MIG-99, 6.25 mg t.i.d.) for migraine prevention were investigated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients ( N = 170 intention-to-treat; MIG-99, N = 89; placebo, N = 81) suffering from migraine according to International Headache Society criteria were treated for 16 weeks after a 4-week baseline period. The primary endpoint was the average number of migraine attacks per 28 days during the treatment months 2 and 3 compared with baseline. Safety parameters included adverse events, laboratory parameters, vital signs and physical examination. The migraine frequency decreased from 4.76 by 1.9 attacks per month in the MIG-99 group and by 1.3 attacks in the placebo group ( P = 0.0456). Logistic regression of responder rates showed an odds ratio of 3.4 in favour of MIG-99 ( P = 0.0049). Adverse events possibly related to study medication were 9/107 (8.4%) with MIG-99 and 11/108 (10.2%) with placebo ( P = 0.654). MIG-99 is effective and shows a favourable benefit-risk ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for Controlled Trials of Drugs in Migraine: Second Edition
International Headache Society Clinical Trials Subcommittee, Tfelt-Hansen, P., Block, G., Dahlöf, C., Diener, H.-C., Ferrari, M., Goadsby, P., Guidetti, V, Jones, B., Lipton, R., et al. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.00117.x · Cited by 698
Self-citation
Cited by
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Holland, S., Silberstein, S. D., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d0c · Cited by 347
Differential Effectiveness of Placebo Treatments: A Systematic Review of Migraine Prophylaxis
Meissner, K., Fässler, M., Rücker, G., Kleijnen, J., Hróbjartsson, A., Schneider, A., Antes, G., & Linde, K. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.10391 · Cited by 301
Metadata
- Authors
- Diener, H., Pfaffenrath, V, Schnitker, J., Friede, M., Zepelin, H.-H. H.-V., & on behalf of the Investigators
- Venue
- Cephalalgia
- Publisher
- SAGE Publications
- Published
- 2005-11
- Volume
- 25
- Issue
- 11
- Pages
- 1031-1041
- ISSN
- 0333-1024 (ISSN-L)
- 1468-2982
- OpenAlex
- W2019598946
- Cited by
- 160
- References
- 1
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of 6.25 mg t.i.d. Feverfew CO2-Extract (MIG-99) in Migraine Prevention — A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1111/j.1468-2982.2005.00950.x
- The paper
- Diener, H., Pfaffenrath, V, Schnitker, J., Friede, M., Zepelin, H.-H. H.-V., & on behalf of the Investigators. (2005). Efficacy and Safety of 6.25 mg t.i.d. Feverfew CO2-Extract (MIG-99) in Migraine Prevention — A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study. Cephalalgia. https://doi.org/10.1111/j.1468-2982.2005.00950.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.